The Southeast Cancer Control Consortium, Inc. is a cooperative group of 18 communities, 14 as components and 4 as affiliates. These are located in an area including eastern Tennessee, 2 border cities of southern Virginia, throughout North Carolina and South Carolina, and 2 locations in Georgia. The catchment of these referral communities is estimated at 7.7 million. Demography of the area reflects a low population density, limited socioeconomic and education development, and a black-white population of approximately twice the national average. The consortium has approximately 90 participating oncologists, with a community leader who is responsible for local coordination of clinical trials.l There are trained support personnel in these communities, and data management is achieved by trained, competent data coordinators. Each of these communities have completed the prescribed assurances for NCI/CTEP/DCPC, and clinical trials from 3 research bases (Cancer Center of Wake Forest University, Cancer and Leukemia Group B, and the National Surgical Adjuvant Project for Breast and Bowel Cancers) have been made available to community participants. The program is coordinated by the Headquarters Office, which provides flow of protocols and protocol communications, IRB recommendations and approval, training programs and quality assurance audit support to our research bases. Participants of the CCOP Consortium have accrued 748 registrations, or 629.9 credits, in the 01-02 years. Our cancer control and prevention goals will include that of a community cancer control program which will have a broad population impact. A unique method of reaching the population base is being devised to encourage lifestyle modifications and focus on early detection, especially in high- risk populations, as a method of reducing the morbidity and mortality of cancer. The program is designed to cross the entire ethnic socioeconomic group. Major emphasis will be placed on community volunteer participation in local execution of cancer control protocols. In addition to expanding our clinical trials recruitment, it is the intention of this organization to implement an effective cancer education and prevention program in these communities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA045808-04
Application #
3558710
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1987-07-01
Project End
1995-05-31
Budget Start
1990-06-01
Budget End
1991-05-31
Support Year
4
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Southeast Cancer Control Consortium
Department
Type
DUNS #
876940532
City
Winston-Salem
State
NC
Country
United States
Zip Code
27104
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7

Showing the most recent 10 out of 215 publications